ClinicalTrials.gg
CompletedNCT04711213Updated Jan 15, 2021

A Clinical Study to Assess the Efficacy and Safety of SED80 for Use in Cataract Surgery

A Phase 2 interventional study of Dexamethasone Dose 1 and Dexamethasone Dose 2 in Cataract in Inflammatory Ocular Disorders, sponsored by iDrop, Inc.. Completed at 1 site in El Salvador. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2021-01-15.

Sponsored by iDrop, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2020, 6 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

Patients at least 40 years of age who are undergoing cataract surgery will be randomized to receive treatment with one of four groups of dexamethasone ophthalmic suspension or placebo eye drops to determine if the drops decrease inflammation and pain inside the eye and are safe after cataract surgery.

Read the detailed description

"Patients undergoing traditional cataract surgery routinely develop inflammation and pain. This study will evaluate 4 arms of either dexamethasone or placebo.

02

Conditions studied

  • Cataract in Inflammatory Ocular Disorders

Browse trials for

03

In context

Cataract

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

This study's enrollment of 60 is below the median of 79 across 1,094 interventional studies indexed under Cataract.

Browse Cataract studies →

Lead sponsor

iDrop, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing traditional cataract surgery.

Exclusion criteria

Exclusion Criteria:

  • Patients with unusual ocular conditions.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Dexamethasone Dose 1

    Drug: Dexamethasone Dose 1

  • Active comparator
    Dexamethasone Dose 2

    Drug: Dexamethasone Dose 2

  • Placebo comparator
    Placebo Dose 1

    Drug: Placebo Dose 1

  • Placebo comparator
    Placebo Dose 2

    Drug: Placebo Dose 2

Interventions

  • DrugDexamethasone Dose 1

    Dexamethasone ophthalmic suspension dose 1

  • DrugDexamethasone Dose 2

    Dexamethasone ophthalmic suspension dose 2

  • DrugPlacebo Dose 1

    Placebo suspension dose 1

  • DrugPlacebo Dose 2

    Placebo suspension dose 2

06

What researchers measure

Primary outcomes

  1. Ocular inflammation

    Measuring Anterior Cell Count

    Time frame: Day 8

Secondary outcomes

  1. Ocular Pain

    Measuring patient ocular pain using an 11-point visual scale

    Time frame: Day 8

07

Study locations

1 site
  • Centre De. Oftalmologia
    San Salvador, El Salvador
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Oct 2020, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2020
First posted
Jan 15, 2021
StartActual
Sep 14, 2020
Primary completionActual
Oct 31, 2020
CompletionActual
Nov 15, 2020
Last update
Jan 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04711213
Lead sponsor
iDrop, Inc.
Responsible party
Sponsor
First posted
Jan 15, 2021
Start date
Sep 14, 2020
Primary completion
Oct 31, 2020
Completion
Nov 15, 2020
Last update
Jan 15, 2021

Study contacts

Gabriel Casada, MD
principal investigator · President - Centre De. Oftalmolgia

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion